Physician profile
Javier Way
NPI 1114680592
$416.56
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.96 · 2022: $372.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $149.81 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.25 | 2022 | |
| Sunovion Pharmaceuticals INC. | $46.07 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $45.49 | 2021-2022 | |
| Lundbeck LLC | $38.42 | 2022 | |
| Almatica Pharma LLC | $30.07 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $25.65 | 2022 | |
| Neurocrine Biosciences, INC. | $18.52 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.28 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Way listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.